Advertisement

Topics

Companies Related to "approves Ironwood Duzallo hyperuricemia related gout" [Most Relevant Company Matches] RSS

06:27 EDT 26th September 2018 | BioPortfolio

Here are the most relevant search results for "approves Ironwood Duzallo hyperuricemia related gout" found in our extensive corporate database of over 50,000 company records.

Showing "approves Ironwood Duzallo hyperuricemia related gout" Companies 1–25 of 1,600+

Extremely Relevant

Ironwood Pharmaceuticals, Inc. 

Ironwood Pharmaceuticals (NASDAQ:IRWD) is a commercial biotechnology company focused on creating medicines that make a difference for patients, building value for our fellow shareholders, and empowering our passionate team. We are commercializing two innovative primary care products: linaclotide, the U.S. branded prescription market leader for adults with ...


Ironwood Pharmaceuticals, Inc. & Astellas Pharma Inc.

Ironwood Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology company focused on creating medicines that make a difference for patients, building value for our fellow shareholders, and empowering our passionate team. We are commercializing two innovative primary care products: linaclotide, the U.S. branded prescription market leader for adults with...

Almirall, S.A. and Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood's GC-C agonist, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. Ironwood also has a gro...


Relevant

Forest Laboratories, Inc. & Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood's GC-C agonist, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. Ironwood also has a gro...

Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood's GC-C agonist, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. Ironwood also has a growing pi...

Gout & Uric Acid Education Society

Formed in September 2005, the Gout & Uric Acid Education Society has a comprehensive educational brochure, as well as a user-friendly Web site for patients, caregivers, family members and healthcare providers. For more information about gout and the Gout & Uric Acid Education Society, please visit www.gouteducation.org. Gout Awareness Day is sponsored by Ardea Biosciences, Inc., EnzymeRx, LLC., No...

Ironwood Pharmaceuticals, Inc. and Almirall

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Ironwood is located in Cambridge, Mass.

Ironwood Pharmaceuticals, Inc. and AstraZeneca

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Ironwood is located in Cambridge, Mass. To learn more, visit www.ironwoodpharma.com.

Ironwood Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc.

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Ironwood is located in Cambridge, Mass. To learn more, visit www.ironwoodpharma.com.

The Gout & Uric Acid Education Society

Formed in September 2005, the Gout & Uric Acid Education Society has a comprehensive educational brochure, as well as a user-friendly Web site for patients, caregivers, family members and health care providers. For more information about gout and the Gout & Uric Acid Education Society, please visit www.gouteducation.org.

Depomed, Inc. & Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood’s GC-C agonist, is in Phase 3 clinical development for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. The efficacy portion of linaclotide’s ...

Ironwood Pharmaceuticals, Inc. and Bionomics Limited

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood’s GC-C agonist, is an investigational drug for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). The efficacy portion of linaclotide’s dev...

Phoenix Pharmacologics Inc.,

Phoenix Pharmacologics Inc., with its principal headquarterslocated in, San Diego, California, is a privately-held emerging biopharmaceutical company that specializes in developing drugs to treat cancer and related disorders. Two of its protein drugs are in late stage clinical trials: ADI-PEG 20 for the treatment of hepatocellular carcinoma and metastatic melanoma,and Uricase-PEG 20 for the treatm...

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...

Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc.

Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our team to passionately pursue excellence. We discovered, developed and are commercializing linaclotide, which is approved in the United States and a number of...

Actavis plc and Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our team to passionately pursue excellence. We discovered, developed and are commercializing linaclotide, which is approved in the United States and a number of...

Ironwood Pharmaceuticals, Inc. and Exact Sciences Corp.

Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our team to passionately pursue excellence. We discovered, developed and are commercializing linaclotide, which is approved in the United States and a number of...

Ironwood Pharmaceuticals , Inc.

IW-1973 and IW-1701 are investigational clinical compounds from Ironwood’s library of pharmacologically distinct soluble guanylate cyclase (sGC) stimulators. The stimulation of sGC is a clinically validated approach with broad therapeutic potential. Found throughout the body, sGC is an enzyme that is activated by the key regulator nitric oxide (NO) to...

Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA(TM) (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase®, from Duke University and Mountain View Pharmaceuticals, Inc. Savient al...

Forest Laboratories, Inc. and Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals (NASDAQ:IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our team to passionately pursue excellence. We discovered, developed and are commercializing linaclotide, which is approved in the United States and a number of ...

Regeneron Pharmaceuticals, Inc.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-re...

Probably Relevant

EnzymeRx, LLC

EnzymeRx, LLC is a private, clinical stage biotechnology company developing enzyme-based therapeutics. Our lead product pegsitacase is in phase 1 clinical studies and being developed for the treatment of refractory gout, treatment and prophylaxis of tumor lysis syndrome, and other indications, and we are actively building our preclinical pipeline. For more...

WholesalePharmacy.com

WHOLESALEPHARMACY.COM:Here we help you find quality healthcare and pharmaceutical services online at affordable wholesale prices. Wholesale prescription orders are reviewed by licensed U.S. physicians. Final prescription is issued by FDA approved U.S. pharmacies. We do NOT deal in generic medications or with non-licensed physicians outside of the United States. Most of the discounted wholesale pre...

Ironwood Pharmaceuticals, Inc. and AstraZeneca Pharmaceuticals Co., Ltd.

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its i...

Savient Pharmaceuticals

Savient Pharmaceuticals, Inc. is a specialty pharmaceuticals company engaged in developing, manufacturing, and marketing pharmaceutical products that address unmet medical needs in both niche and broader markets. The company has initiated Phase 3 trials for its flagship product Puricase® (PEG-uricase) , for treatment-failure gout. Savient currently markets Oxandrin® (oxandrolone, USP) in the U.S...


More From BioPortfolio on "approves Ironwood Duzallo hyperuricemia related gout"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks